Clinical Trial Update: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether adding ponatinib to dose-adjusted EPOCH, with or without rituximab, improves outcomes in newly diagnosed Philadelphi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Ponatinib (ponatinib)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: University of Washington | Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Status: RECRUITING